96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction wiht Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/05 → 4/30/12

Funding

  • GlaxoSmithKline: $82,683.00